CA
NZ
UK
AU
IND
US
…
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
AN2 Therapeutics Inc is a Nasdaq-listed, development-stage biopharmaceutical company; public disclosures are limited on its pipeline and technology. Its long-term growth drivers would likely be successful clinical development, regulatory approvals and strategic partnerships that could support commercialization and revenue scaling. Investors may find the company attractive for potential upside from clinical milestones if program progress and funding hold.
Key investment risks include clinical and regulatory failure, high cash burn and financing needs that could dilute shareholders, limited liquidity typical of small-cap biotech and competitive pressures in the therapeutic areas it targets.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
| Net income | -35.17M | -51.32M | -64.73M | -41.47M | -21.47M |
| Selling general administrative | 13.34M | 14.07M | 14.76M | 12.75M | 4.67M |
| Selling and marketing expenses | - | - | 14.75M | - | - |
| Ebit | - | -51.32M | -64.73M | -42.26M | -21.57M |
| Ebitda | -38.11M | 3.23M | 4.90M | -42.26M | -21.57M |
| Depreciation and amortization | - | 54.55M | 69.64M | -1.21M | 0.10M |
| Operating income | -38.11M | -54.55M | -69.64M | -42.26M | -21.57M |
| Other operating expenses | 38.11M | 54.55M | 69.64M | 42.26M | 21.57M |
| Interest expense | - | - | - | 0.51M | 0.07M |
| Interest income | 2.93M | 5.47M | 4.86M | 1.35M | 0.07M |
| Net interest income | 2.93M | 5.47M | 4.86M | 1.35M | 0.07M |
| Income tax expense | - | - | -0.07M | 0.51M | -0.07M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 38.11M | 54.55M | 69.64M | 42.26M | 21.57M |
| Total other income expense net | 2.94M | 3.23M | 4.90M | 1.31M | 0.03M |
| Net income from continuing ops | -35.17M | -51.32M | -59.68M | -40.96M | -21.54M |
| Net income applicable to common shares | - | - | - | -42.78M | -28.06M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 61.95M | 92.09M | 138.74M | 102.56M | 65.32M |
| Other current assets | 1.04M | 2.34M | 1.81M | 2.56M | 1.55M |
| Total liab | 8.89M | 10.24M | 14.04M | 7.19M | 112.73M |
| Total stockholder equity | 53.06M | 81.85M | 124.70M | 95.37M | -47.41M |
| Deferred long term liab | - | - | - | - | 1.72M |
| Other current liab | 5.70M | 6.92M | 11.37M | 5.01M | 2.33M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -240.95M | -205.78M | -154.46M | -89.72M | -47.38M |
| Other liab | - | - | - | - | 0.01M |
| Other assets | - | - | 0.00M | 0.72M | 1.72M |
| Cash | 19.94M | 21.35M | 15.65M | 27.22M | 12.10M |
| Total current liabilities | 8.72M | 10.24M | 14.04M | 7.19M | 3.40M |
| Net debt | -19.94M | -21.35M | -15.65M | -27.17M | -12.10M |
| Short term debt | - | - | - | 0.05M | - |
| Short long term debt total | - | - | - | 0.05M | - |
| Other stockholder equity | 293.95M | 287.59M | 278.88M | 82.91M | -0.03M |
| Total current assets | 59.94M | 86.26M | 110.51M | 98.62M | 60.11M |
| Long term investments | 2.01M | 5.02M | 27.19M | 3.22M | 3.49M |
| Net tangible assets | - | - | - | 95.37M | -47.41M |
| Short term investments | 38.06M | 62.27M | 91.65M | 68.84M | 46.46M |
| Net receivables | 0.90M | 0.30M | 1.40M | - | - |
| Accounts payable | 3.02M | 3.32M | 2.68M | 2.12M | 1.06M |
| Accumulated other comprehensive income | 0.06M | 0.03M | 0.28M | -0.37M | -0.03M |
| Non currrent assets other | - | 0.80M | 1.04M | 0.67M | 1.72M |
| Non current assets total | 2.01M | 5.83M | 28.24M | 3.94M | 5.21M |
| Capital lease obligations | - | - | 0.00M | 0.05M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 28.31M | 54.59M | -37.64M | -21.77M | -50.02M |
| Change to liabilities | - | - | - | 0.00M | 0.42M |
| Total cashflows from investing activities | 28.31M | 54.59M | -43.28M | -21.77M | -50.02M |
| Total cash from financing activities | 0.11M | 0.37M | 84.99M | 70.36M | 78.53M |
| Change to operating activities | - | - | - | 1.22M | -0.39M |
| Net income | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
| Change in cash | -1.41M | 5.70M | -11.57M | 15.12M | 8.03M |
| Begin period cash flow | 21.35M | 15.65M | 27.22M | 12.10M | 4.07M |
| End period cash flow | 19.94M | 21.35M | 15.65M | 27.22M | 12.10M |
| Total cash from operating activities | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Issuance of capital stock | - | 0.00M | 84.85M | 70.37M | 79.73M |
| Depreciation | - | - | - | -0.69M | - |
| Dividends paid | - | - | - | 1.82M | - |
| Other cashflows from financing activities | 0.11M | 0.37M | 0.47M | 1.81M | 78.53M |
| Change to netincome | - | - | - | 3.78M | 1.03M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.16M | -3.00M | 5.83M | 3.72M | 0.03M |
| Stock based compensation | 6.25M | 8.34M | 8.41M | 4.39M | 0.97M |
| Other non cash items | -1.07M | -3.28M | -2.80M | 0.08M | 0.05M |
| Free cash flow | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics Inc |
-0.17 3.91% |
4.18 | - | - | - | 2.45 | -2.11 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
1300 El Camino Real, Menlo Park, CA, United States, 94025
650 331 9090
21
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph S. Zakrzewski | Co-founder & Independent Chairman | 1962 |
| Mr. Eric E. Easom | Co-founder, CEO, Pres & Director | 1968 |
| Ms. Lucy O. Day CPA | CFO, Sec. & Treasurer | 1959 |
| Dr. Paul Eckburg M.D. | Chief Medical Officer | 1971 |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Sr. Clinical Advisor | 1948 |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder & Head of Biology | NA |
| Mr. Josh Eizen | Chief Legal Officer & Sec. | NA |
| Dr. Sanjay Chanda Ph.D. | Chief Devel. Officer | 1965 |
| Mr. Kevin Krause B.S., M.B.A. | Chief Strategy Officer | 1975 |
| Ms. Jennifer Huber | Sr. VP of Regulatory Affairs & Quality | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...